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Abstract
Background: The transmission of drug-resistant HIV in newly identified infected populations has become an
underlying epidemic which can be better assessed with sensitive resistance testing. Since minority drug resistant
variants cannot be detected by bulk sequencing, methods with improved sensitivity are required. Thus, the goal of
this study was to evaluate if transmitted drug resistance mutations at minority levels in Japanese patients could be
identified using highly sensitive allele-specific PCR (AS-PCR).
Materials and Methods: Samples were taken from newly diagnosed HIV/AIDS cases at the National Nagoya
Hospital from January 2008 to December 2009. All samples were bulk sequenced for HIV protease and reverse
transcriptase. To detect minority populations with drug resistance, we used AS-PCR with mutation-specific primers
designed for seven reverse transcriptase inhibitor resistance mutations, M41L, K65R, K70R, K103N, Y181C, M184V,
and T215F/Y, and for three protease inhibitor resistance mutations, M46I/L and L90M.
Results: We studied 149 newly identified HIV cases. Bulk sequencing detected 8 cases with NRTI resistance
mutations (one with A62V, one D67E, one T215D, one T215E, two with T215L and two T215S) and 15 with PI
resistance mutations (one with N88D and 14 with M46I). Results obtained by AS-PCR and bulk sequencing
demonstrated good concordance but the AS-PCR enabled the detection of seven additional drug-resistant cases
(one M41L, two with K65R, two with K70R, and one M184V) in the RT region. Additionally, AS-PCR assays identified
15 additional cases with M46I, five with M46L and four cases with L90M in the protease region.
Conclusions: Using AS-PCR substantially increased the detection of transmitted drug resistance in this population
from 15.4% to 26.8%, further supporting the benefit of sensitive testing among drug-naïve populations. Since the
clinical impact of minority drug-resistant populations is not fully comprehended for all mutations, follow-up studies are
needed to understand their significance for treatment.
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Introduction
The use of combination antiretroviral therapy of (cART) has
resulted in sustained reductions in morbidity and mortality from
HIV infection [1,2]. Five classes of antiretrovirals (ARVs) are
currently available in clinical use in Japan. However, selection
of drug resistance mutations during cART is still a major issue
affecting the clinical efficacy of ARVs and prognosis of HIV
infected individuals [3,4].
A United States Department of Health and Human Services
(DHHS) guideline recommends drug resistance testing for
patients before they begin cART to guide their therapy[5].
Conventional bulk sequencing is used to detect drug resistance
mutations in viral RNA from patient plasma, but the method
generally does not detect mutants that comprise less than 20%
of the viral population in individuals [4-7]. This detection
limitation is a concern, both because transmitted minority
variants might persist at low frequencies and most newly
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diagnosed HIV infections are in persons who have been
infected for several months to years, providing time for drug
resistant viruses with reduced viral fitness to decay to levels
that conventional testing is not able to detect [8-10]. Therefore,
the ability to detect low-frequency variants below 20% would
improve identification of infections involving drug-resistant
viruses and better inform decisions on the selection of active
ARVs, especially for persons initiating treatment with NNRTI
regimens. To detect low-frequency variants, several methods
were developed and used to analyze drug-naïve persons and
drug-experienced persons [11-14]. Several studies have shown
the advantages of highly sensitive drug resistance assays with
women who received intrapartum single-dose nevirapine (SD-
NVP) for the prevention of mother-to-child HIV transmission.
These reports on testing for NVP resistance have found that
drug resistance emerges more frequently and persists for
longer than previously demonstrated by bulk-sequencing.
Persisting minority NVP-resistant viruses may result in poor
virologic responses when subsequent regimens contain
nevirapine-related drugs [15-19].. We previously reported that
highly-sensitive drug resistance testing that is based on allele-
specific real-time PCR can detect minority drug-resistant
variants both in infections reported to be wildtype and
infections involving other resistance mutations as determined
by bulk sequencing. As with majority-level resistance, the
amount of low-frequency resistance in new infections reflects
both the prevalence of cART use in the region and behavior
that is inconsistent with prevention practices for persons on
therapy [20].
Recently, it has been reported that the prevalence of drug-
resistant HIV transmission among newly diagnosed patients
analyzed by bulk sequencing is increasing in Japan, rising from
5.9% in 2003 to 8.3% in 2008 [21]. As the study concluded, this
observation was seen not only for recently infected persons,
but also chronically infected but recently diagnosed cases,
raising concern over the amount of resistance detection lost
due to reversion. Therefore, by use of a highly sensitive
method in the current study we attempted to examine for the
possibility and prevalence of transmitted drug resistant
mutations hidden as minority populations.
Materials and Methods
Ethics statement
Specimens were anonymous residual diagnostic material
from subjects who provided written consent for HIV testing. The
Ethical Committee for Biomedical Science of the National
Institute of Infectious Diseases determined that this testing did
not involve identifiable human subjects and has approved the
study.
Samples
The 192 plasma samples were collected from HIV/AIDS
cases for drug resistance analysis from January 2008 to
December 2009 in National Nagoya Hospital (Table 1). Among
these, 149 cases of newly diagnosed HIV-1 subtype B-infected
ART-naïve individuals were selected and analyzed in this study
(Figure 1). All samples were collected as part of HIV
surveillance studies under Institutional Review Board of
National Institute of Infectious Diseases, and written informed
consent was obtained from each patient. These samples were
directly sequenced for HIV protease (PR) positions 1-99 and
reverse transcriptase (RT) positions 1-240. Drug resistance
mutations were defined according to the mutation list proposed
by Bennett et al. 2009[22]. All testing was performed by the
NIID AIDS Research Center in Tokyo, Japan[21].
Table 1. Demographics of samples.
  2008 2009 Total
Total  75 74 149
Gender male 74 73 147
 female 1 1 2
 unknown 0 0  
Age median(Q1, Q3) 39 38 39
Risk behavior MSM 52 49 101
 Sexual 9 11 20
 MSM/Sexual 8 13 21
 Hemophiliac 1 0 1
 Unknown 5 1 6
VL Median 9.70E+04 7.00E+04 7.90.E+04
 mode 1.10E+05 2.70E+04 1.10.E+05
CD4 average 199.7 225.4 212.0
doi: 10.1371/journal.pone.0083150.t001
Figure 1.  Flow Diagram of sample selection.  Flow diagram
of sample selection for analysis of minority drug resistance
mutations in the HIV-infected patient samples newly diagnosed
at National Nagoya Hospital from 2008 to 2009.
doi: 10.1371/journal.pone.0083150.g001
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RNA extraction and virus template amplification
HIV RNA was extracted by Roche High Pure Viral RNA Kit
from 200uL plasma samples. RNA was reconstituted in 100 uL
of DEPC water and stored at -80°C until use. The HIV
protease-reverse transcriptase (PR-RT) region was amplified
by one-step RT-PCR (TAKARA One Step RNA PCR kit) with
forward primer (DRPRO5 : AGA CAG GYT AAT TTT TTA GGG
A) and reverse primer (DRRT34 : GCT ATT AAG TCT TTT
GAT GGG TCA TA). RT-PCR amplification conditions were
55°C for 40 minutes and 40 cycles of 95°C for 10 seconds,
52°C for 5 seconds, and 72°C for 90 seconds. In the case that
the amplification of RT- PCR did not generate sufficient
template, nested-PCR was performed using forward primer
(PROFWD1F : CAG ATC ACT CTT TGG CAA CGA CC) and
reverse primer (GEN4R : ATC CCT GGG TAA ATC TGA CTT
GC)[23]. Nested-PCR amplification condition was 94°C 1
minute and 30 Cycles of 94°C for 10 seconds, 55°C for 4
seconds and 74°C for 15 seconds.
Real-time PCR (AS-PCR)
To detect minority populations with drug resistance, we used
highly sensitive allele-specific PCR validated for subtype B HIV
as described [17,23]. Briefly, mutation-specific primers were
designed for seven reverse transcriptase inhibitor resistance
mutations, M41L, K65R, K70R, K103N, Y181C, M184V, and
T215F/Y. Results of highly sensitive allele-specific PCR and
population sequencing data were compared for concordance
and presence of additional mutations. The HIV-1 total copy
primers, Com2F and Com4BR, span n.t. 258–420 in RT and
were used with the common probes, Com1P and 2P (Table S1)
[17,23]. For multiple mutation screening, several resistance
mutation-specific reactions can be performed simultaneously.
The cycle number at which the fluorescence emission exceeds
the background fluorescence threshold is the threshold cycle
(CT) and is the unit of measure for comparing the differences in
amplification signals (∆CT) between the total copy and
mutation-specific reactions. All samples were tested in
duplicate with the means of the total copy and mutation-specific
CTs used for the determination of the ∆CT. Each ∆CT cutoff
value for interpreting the presence of drug resistance mutations
was determined previously [23] and were between 8.5 from
10.5 cycles, for validated assay cut-offs ranging from 0.03% to
2.0% mutant, depending on the assay.
Real-time PCRs were initiated with a hot-start incubation at
94°C for 11 minutes before proceeding to 45 cycles of melting
at 94°C for 30 seconds, annealing at 50°C for 15 seconds and
extension at 60°C for 30 seconds. All reactions were performed
in a total volume of 50 uL/well in 96-well PCR plates using iQ5
real-time PCR thermocyclers with optical units (Bio-Rad) and
AmpliTaq Gold polymerase (2.5 U/reaction; Applied
Biosystems). Final reagent concentrations were 320 nM for the
forward and reverse primers, 160 nM probe(s), and 400 mM
dNTPs.
M46I/L primers for real-time-PCR
For this study, new primers for the detection of M46I and
M46L protease inhibitor mutations were constructed as
described before [17,23,24]. As with the RT primers, the
protease mutation-specific primers (Table S2) were designed
to preferentially anneal with the targeted mutation
nucleotide(s), thus having reduced affinity for wild-type
sequences. Specificity was enhanced by creating designed
mismatches at the -2 nucleotide position relative to the primer
3’-end for each primer. Furthermore, to compensate for the
spectrum of polymorphisms present, mixtures of three uniquely
designed forward primers were required to detect M46L.
Mutation-specific primer mixtures were experimentally
evaluated and the ratios that best balanced differences in
primer avidities and minimized cross-interference in primer
annealing were selected.
Site-directed mutagenesis and cloning
M46I and M46L mutant clones for plasmid development were
constructed by site-directed mutagenesis using HXB2 as a
template. These constructs were used as positive control to
verify the M46I/L primers and probes. To insert M46I or M46L
mutations into HXB2, PCR with KODplus was performed using
a pair of complementary primers (M46I-forward primer : GAA
GAT GGA AAC CAA AAA TaA TAG GGG GAA TTc GAG G,
M46L(ttg)-forward primer : GAA GAT GGA AAC CAA AAt TGA
TAG GGG GAA TTG GAG G , M46L(ctg)-forward primer : GAA
GAT GGA AAC CAA AAc TGA TAG GGG GAA TTG GAG G),
and reverse primer : CTG GCA AAC TCA TTT CTT CTA ATA
CTG TAT CAT CTG CTC C). PCR amplification conditions
were 94°C for 2 minutes and 35 cycles of 98°C for 10 seconds,
68°C for 2 minutes and 30 seconds.
Evaluation of the new protease assays on plasmids and
clinical samples
HXB2-M46I, HXB2-M46L and HXB2 (wild-type) plasmids
were used in the preliminary selection of primer mixtures that
provided the greatest sensitivity and specificity. The absolute
mutation detection limits for the primer mixtures, that is, the
greatest ΔCT that was able to distinguish mutant viruses from
wild-type, were estimated from triplicate testing of mutant clone
serial dilutions. The assays evaluated mutation-containing
sequences at frequencies between 100%-0.0001% in a wild-
type background, with each dilution having same total plasmid
copies. The ΔCTs generated from the mutant dilutions were
compared to the ΔCTs generated with the wild-type plasmids
alone. Solely for the purpose of comparing relative assay
detection limits with finite virus sequences, the ΔCT within the
linear dilution range (R2>0.995) that was equivalent to a
frequency increase of 0.5 log10 above the wild-type mean ∆CT
was chosen as the absolute assay detection limit. Selecting the
detection limit in this manner provided an adequate buffer
against variability in wild-type sequences and also took into
account the PCR efficiency of the assay (slope of the dilution
curve).
To evaluate cutoff values of M46I and M46L in patient
samples, PR-RT sequences derived from ART-naïve patients
were analyzed by real-time PCR. Forty-two PR-RT region
sequences derived from 16 patients were cloned by TA-cloning
to serve as heterogeneous wild-type sequences. Fifty-five
samples with protease M46I were obtained from 20 individuals
and 22 samples with M46L were obtained from 12 individuals.
Transmitted Minor-Variants of Drug-Resistant HIV
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To increase the stringency of assay evaluations, specimens
with substantial numbers of polymorphisms in primer binding
sites were also included.
Assessing mutation associations in mutation-specific
amplicons
To evaluate whether additional information on resistance
mutations could be gained from the real-time PCR assays, we
performed bulk sequencing (BigDye reagent, Prism 3130xl
analyzer, Applied Biosystems) of the products from M46I/L or
L90M-specific reactions to assess mutation linkage. Mutation-
specific amplicon sequences were compared to their respective
sample bulk sequence for evidence of nucleotide differences.
Any other resistance mutation(s) found in the mutation-specific
amplicons would indicate that they were on the same viral
strand(s) as the mutation that was specifically targeted by the
primers.
Phylogenetic analysis
Protease sequences were aligned by means of the clustal-W
program with a set of reference sequences recommended by
the Los Alamos sequence database (http://www.hiv.lanl.gov/
content/index). The results of the alignment were then
analyzed by the neighbor-joining method using MEGA5 [24,25].
In order to analyze the relationship between M46I/L-positive
amplicon sequences and bulk sequences, we extended the
M46I/L-positive amplicon by using the PRO2L reverse primer
(Table S1B), which allowed sequencing from PR codon 47 to
RT codon 36 of these M46I/L-positive amplicons (270 bp). In
the case of L90M amplicon analysis, 209 bp DNA fragments
extending from amino acid 20 in PR to amino acid 89 in PR
were represented in the phylogenetic tree. The phylogenetic
relatedness of these mutation-containing amplicons excluding
the resistance codon position were represented in trees
constructed using Kimura 2-parameter model with a discrete
gamma distribution [1 +G] and 500 bootstrap replications in
MEGA5.
Statistics
The Mann-Whitney U test was used to test for differences in
CD4 counts and VL between the groups with minority drug
resistance mutations and those without minority drug
resistance mutations.
Results
Minority M46I could be detected as low as 0.04% and
M46L could be detected as low as 0.03% in site-
directed mutant clones
Relative limits of detection were compared in a simple
laboratory setting using serial dilutions of HXB2-M46I or HXB2-
M46L in backgrounds of HXB2 wildtype plasmid. The ΔCT that
was equivalent to a 0.5 log greater reactivity than the wild-type
mean ΔCT on the dilution curve (M46I : ∆CT=15 cycles, M46L :
∆CT=17 cycles) was used to compare assay sensitivities
(Figure 2). This approach yielded detection limits of 0.04% and
0.03% for M46I and M46L, respectively. As this was derived
from cloned sequences this is a theoretical detection limit
against which clinical specimens are evaluated.
High sensitivity and specificity of M46I/L detection
assays confirmed with clinical samples
Assay cutoff values intended for population-wide clinical
screening were established using 42 cloned wild-type
sequences derived from 14 patient-derived specimens
Figure 2.  Mutation-specific assay reactivity on plasmids.  Cloned M46I (A.) and M46L (B.) mutant virus template was diluted
10-fold, from 100% to 0.0001%, in backgrounds of wild-type sequence to determine assay detection limits. Plotted are the mean
ΔCT versus log10 of the mutant dilution series. The lower detection limit (lower dotted line) was placed at the ΔCT equivalent to 0.5
log10 below (0.5-log greater reactivity than) the wild-type ΔCT. For comparison, the mutant virus frequency equivalences for the
established clinical cutoffs are also shown (dashed line).
doi: 10.1371/journal.pone.0083150.g002
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collected by NIID from 2005-2007. The assay cutoffs selected
based on plasmid sequences were evaluated against clinical
specimens using a total of 55 samples with sequence-
detectable M46I mutation and a total 22 samples with
sequence-detectable M46L mutation. The resulting distribution
of collated ΔCTs from the wild-type samples supported a ΔCT
cutoff of 11 cycles for M46I clinical testing (ΔCTs ranged from
16.39–26.65 cycles) (Figure 3 and Table S3). Extrapolating
from the dilution curve for cloned M46I sequences, this cycle
difference corresponded to a frequency mean of 0.54% mutant
virus (see Table S3). At this cutoff, all 55 genotyped M46I
samples were positive (ΔCTs ranged from 1.39 to 10.1 cycles,
Figure 3 and Table S3). For M46L assay, ΔCT cutoff was 9
cycles to avoid low-level amplification from spurious primer
binding against clinical quasispecies specimens; this cutoff
placement corresponded to a frequency mean of 4.01% mutant
virus. All genotype M46L samples were positive (ΔCT ranged
from 0.88 to 8.95 cycles) (Figure 3 and Table S3). Because of
unusual polymorphisms, some samples comprised almost
entirely of mutant virus produced ΔCTs near the cutoff. In these
situations, elevated ΔCTs resulting from weak primer binding
could be interpreted as mutant viruses present at low
frequencies. Hence, this testing format is best-suited to provide
highly specific population-level resistance screening and is not
necessarily applicable to mutant virus quantitation.
AS-PCR method identifies a greater prevalence of
transmitted HIV drug resistance
Samples from a total of 149 subtype B cases were collected
at Nagoya Medical Center for drug resistance testing. Drug
Figure 3.  Assay reactivity with wild-type and M46I/L
mutation clinical samples.  Dotted ΔCT values from clinical
samples with sequence-detectable mutations and with wild-
type sequences are shown. The range of reactivity for each
assay is shown for wild-type and mutant samples. The mean of
ΔCT (bar) for each group is indicated. Assay cutoffs (dotted
horizontal line) were established to exclude all wild-type viruses
from detection. PC; Positive clones with M46I/L, NC; Negative
clone with no M46I/L(wild type).
doi: 10.1371/journal.pone.0083150.g003
resistance mutations were initially analyzed by bulk
sequencing, and 23 cases were found to possess drug
resistance mutations. As summarized in Table 2, all resistant
mutations were found as sole mutation, one with A62V, one
with D67E and six cases of intermediates at codon 215 (one
with T215D, one with T215E, two cases of T215L and two
cases of T215S), one with N88D and 14 cases of M46I
mutation were detected by conventional bulk sequencing
analysis, yielding a drug resistance mutation prevalence of
15.4% (23/149 cases) (Table 2). The sensitive screening
detected an additional one case of M41L (0.67%), two cases of
K65R (1.34%), two cases of K70R (1.34%), one case of
M184V (0.67%), 15 cases of M46I (19.46%), 5 cases of M46L
(3.36%) and 4 cases of L90M (2.68%) as minority-level drug
resistance mutations (Table 2). The identified A62V, D67E,
T215E, T215S and N88D mutations detected by bulk
sequencing were not targeted by AS-PCR, and therefore were
not included in determining changes in mutation frequency. All
17 mutations detected by bulk sequencing analysis that were
also targeted by AS-PCR were likewise detected by the
sensitive PCR method. The combined prevalence of drug
resistance mutations in the total of 149 cases was 26.8%
(40/149 cases) (Table 2). In one case, six mutations, M41L,
K70R, M184V, M46I, M46L and L90M were detected as
minority mutations by the highly sensitive assays (ID 29).
These six mutations were undetectable by bulk sequencing
analysis. In other cases, K70R and M46I were detected (ID
22), and M46I and M46L were detected in another case as
minority drug resistance mutations (ID 5). Of those with
minority drug resistance mutations, 11 cases were from 2008
and 12 cases were from 2009. The majority of patients with
minority variants were MSM (90.9% in 2008 and 83.3% in
2009) and Japanese, and no significant differences were
observed in viral load and CD4 counts by Mann-Whitney U test
(p=0.17 and p=0.308, respectively) for persons with or without
mutations. Though all of the samples from 2008 were
Japanese patients, three cases from 2009 were non-Japanese
patients (Table 2).
Sequence analysis of M46I and M46L-specific
amplicons showed that these mutations were not
linked to L90M in the patient samples
To analyze the linkage between drug resistance mutations,
we directly sequenced positive M46I/L or L90M-specific PCR
products to ascertain whether additional genotypic information
could be obtained from those amplicons. In ID 29, the I72V
polymorphism observed in the bulk sequence was detected in
M46L and L90M amplicons, but not in the M46I amplicon
(Table 3). Additionally, M46I/L mutations were not detected in
the minority L90M amplicon indicating these mutations were
not linked. In ID 27, A71T was detected in the M46L amplicon,
but this mutation was not found in the M46I amplicon or the
bulk sequence (Table 3). In ID 22, the M46I amplicon matched
the bulk sequence.
Transmitted Minor-Variants of Drug-Resistant HIV
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Phylogenetic relatedness of minority and bulk
sequence-detectable resistance mutations
Phylogenetic analysis conducted on all the protease
sequences produced a pattern consistent with good separation
of unrelated sequences even though they were not supported
at the roots by significant bootstrap values due to somewhat
short sequence lengths (Figure 4A). However, the branch tips
show strong bootstrap support for the relatedness of minority
variants to the patient bulk sequences from which they were
derived. Moreover, some of the patients with bulk sequence-
detectable M46I appeared to group together with relatively high
bootstrap values (pairs X and Y, Figure 4A) and may represent
infections linked within transmission clusters. The sequences
Table 2. Characteristics of HIV/AIDS patients with drug resistance mutations.
       Bulk-seq AS-PCR
ID Gender Risk behavior Year Nationality VL CD4 RT mutations PR mutations RT mutations PR mutations
1 M MSM 2008 Japan 2.0.E+04 402 A62A/V    
2 M Heterosexual 2008 Japan 1.2.E+06 14  N88D/N   
3 M Heterosexual 2008 Japan 3.1.E+05 38 T215L  T215F*  
4 M MSM/Heterosexual 2008 Japan 5.8.E+05 222 D67D/E   M46I
5 M MSM 2008 Japan 2.6.E+04 481    M46I, M46L
6 M MSM 2008 Japan 1.7.E+06 10    M46I
7 M MSM/Heterosexual 2008 Japan 4.1.E+05 39 T215S    
8 M MSM 2008 Japan 2.2.E+05 14  M46I  M46I
9 M MSM 2008 Japan 1.5.E+04 356    L90M
10 M MSM/Heterosexual 2008 Japan 1.2.E+05 28 T215S    
11 M MSM/Heterosexual 2008 Japan 1.3.E+05 348  M46I  M46I
12 M MSM 2008 Japan 2.1.E+04 391   K65R  
13 M MSM 2008 Japan 2.1.E+05 553  M46I  M46I, L90M
14 M Heterosexual 2008 Japan 6.7.E+04 153  M46I  M46I
15 M MSM 2008 Japan 2.2.E+05 10  M46I  M46I, M46L
16 M MSM 2008 Japan 1.2.E+03 45 T215L  T215F* M46I
17 M MSM 2008 Japan 2.6.E+04 750  M46I  M46I
18 M MSM 2008 Japan 1.1.E+05 146  M46I  M46I
19 M MSM 2008 Japan 8.4.E+04 11    M46I
20 M MSM 2008 Japan 1.4.E+05 86  M46I  M46I
21 M MSM 2008 Japan 1.1.E+05 1050    M46I
22 M MSM 2008 Japan 2.2.E+04 154   K70R M46I
23 M MSM 2009 Japan 7.2.E+03 319    M46L
24 M MSM 2009 Japan 2.9.E+04 185    M46I
25 M Heterosexual 2009 Japan 1.6.E+04 290 T215D  T215Y**  
26 M MSM/Heterosexual 2009 Japan 2.7.E+04 442  M46I  M46I
27 M MSM 2009 Brazil 8.6.E+04 14  M46I  M46I, M46L
28 M MSM 2009 Argentina 2.0.E+05 28    M46I
29 M MSM 2009 Japan 4.5.E+05 3   M41L, K70R, M184V M46I, LM46L, L90M
30 M MSM 2009 Japan 1.7.E+05 nt  M46I  M46I
31 M MSM 2009 Japan 2.9.E+05 32 T215E  T215Y  
32 M MSM 2009 Japan 1.1.E+05 833  M46I  M46I
33 M MSM 2009 Japan 4.1.E+04 426  M46I  M46I
34 M MSM 2009 Japan 1.2.E+07 441  M46I  M46I
35 M MSM 2009 Australia 1.5.E+04 1    M46I
36 M MSM 2009 Japan 2.2.E+04 324    L90M
37 M MSM 2009 Japan 6.0.E+04 373    M46I
38 M MSM 2009 Japan 2.9.E+04 nt   K65R  
39 M Heterosexual 2009 Japan 4.5.E+03 974    M46I
40 F Heterosexual 2009 Japan 8.0.E+04 nt    M46I
41 M MSM 2009 Japan 1.4.E+04 300    M46I
Subtotal      8(5.3%) 15(10.1%) 8(5.3%) 32(21.5%)
Total       23/149(15.4%) 40/149(26.8%)  
* T215F detection primers can detect T215L, T215I and T215V. **T215Y detection primers can detect T215D, T215H and T215N.
doi: 10.1371/journal.pone.0083150.t002
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within each X and Y pair were 100% identical in the 270 bp
analyzed, with the exception of ≤3 mixed-base positions that
included the nucleotide of the paired patient. In assessing the
relatedness of the four detected minority L90M to infections
that have the PR M46I mutation, three L90M were from
patients that were wildtype at codon 46, the fourth was ID 13
which was also an M46I case (Figure 4B).
Discussion
In this study, we used a highly sensitive method to screen for
minority drug-resistant populations in 149 cases of newly
diagnosed HIV-infected patients. An additional six drug
resistance mutations in the RT region and thirty drug resistance
mutations in PR region were detected as minority-level drug
resistance mutations. For the ten codons associated with
resistance (RTI mutations: M41L, K65R, K70R, K103N, Y181C,
M184V and T215F/Y, PI mutations: M46I/L and L90M) the
prevalence of detectable drug resistance mutations increased
from 15.4% to 26.8% using the highly sensitive assays. A
previous surveillance study in Japan using bulk sequencing
reported that in 2008 the prevalence of transmitted drug
resistance was 8.3% [21]. Therefore, drug resistance mutation
surveillance analyzed by bulk sequencing underestimates
transmitted drug resistance, which potentially has both clinical
and epidemiologic implications.
The epidemiologic implications of increased transmitted
resistance may reflect prevention failures in persons who know
they are infected and transmit HIV to their partners. The clinical
implications of minority drug resistance center around the
impact of these viruses on ART responses. Previous studies
have reported that minority NNRTI-resistant variants are
associated with increased risk of virologic failure in patients
receiving first-line NNRTI-based ART regimens [20,26-32].
These findings are important because NNRTI resistance is the
most commonly transmitted resistance in the US and Europe
[33,34]. However, no evidence of either majority or minority
NNRTI-resistance was found in this study, a unique finding that
is explained by the historically infrequent use of NNRTIs in
ART regimens in Japan. Instead, we note that the NRTI K65R
Table 3. Genetic linkage of M46I/L or L90M and other
mutations.
Sample Sequences Mutations
ID 29 Direct-sequencing I62V, L63P, I72V, T74A, V77I, I93L
 M46I amplicon* M46I, I62V, L63P, T74A, V77I
 M46L amplicon* M46L, I62V, L63P, I72V, T74A, V77I
 L90M amplicon** I62V, L63P, I72V, T74A, V77I, L90M
ID 27 Direct-sequencing M46I, E21R, R41K, I62V, L63P, L89I, Q92K, I93L
 M46I amplicon* M46I, I62V, L63P
 M46L amplicon* M46L, I62V, L63P, A71T
ID 22 Direct-sequencing E35D, M36I, L63P, H69K, V77I
 M46I amplicon* M46I, L63P, H69K, V77I
* M46I and M46L amplicons were spanned from M46 to N88.
** L90M amplicon was spanned from I15 to L90.
doi: 10.1371/journal.pone.0083150.t003
Figure 4.  Phylogenetic tree of samples with or without
minority variants of M46I/L or L90M drug resistance.  A
neighbor-joining phylogenetic tree of all protease sequences
using the Kimura 2-parameter model was generated in
MEGA5. Numbers shown are IDs of patients with detectable
minority drug resistance. Open circles (black color) are virus
with M46I detected by bulk sequencing. A. Solid squares (red
color) indicate sequences of M46I-specific amplicons and solid
triangle (red color) indicate sequences of M46L amplicons;
open circles (red color) indicate bulk sequences for persons
with minority M46I/L mutations; X and Y are pairs of closely
related transmitted M46I sequences. B. Solid squares indicate
L90M-specific amplicon sequences; open squares indicate bulk
sequences for persons with minority L90M mutations. Open
circles (black color) are virus with M46I detected by bulk
sequencing. Abbreviations of subtype B references: B-1; B.NL.
00.671 00T36.AY423387, B-2; B.US.98.1058 11.AY331295,
B-3; B.FR.83.HXB2 LAI IIIB BRU.K03455, B-4; B.TH.
90.BK132.AY173951, B-5; B.US.98.15384 1.DQ853463.
doi: 10.1371/journal.pone.0083150.g004
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and M184V mutations were both detected as minority
populations. As major mutations K65R and M184V reduce the
clinical efficacy of TDF and 3TC/FTC, respectively [35-37],
however their clinical impact as minority mutations is not fully
clear.
A previous study demonstrated no impact on therapy
responses in patients who had minority-level K65R and M184V
mutations when provided regimens that included protease
inhibitors; however; because of the small number of patients
representing different treatment regimens in that study, the
bearing of these mutations could not be fully evaluated [29].
Additional studies are needed to assess clinically significant
frequencies of different NRTI-resistant variants on various
treatment regimens. In the present study, one of the 149 cases
evaluated possessed six drug resistance mutations as minority
variants (Table 2). Genotype interpretation by the Stanford HIV
Drug Resistance Database showed that the patient possessed
high-level resistance to NRTIs and some PIs. It was not
possible to follow the clinical course of this patient to elucidate
the significance of minority variants on subsequent cART.A
major finding in this study was the high prevalence of
transmitted PI resistance (20%) which accounted for about two-
thirds the overall transmitted resistance. The high prevalence
of transmitted PI resistance is supported both by detection at
majority as well as minority variant levels, the latter comprising
more than half of the transmitted PI cases. The high
prevalence of PI resistance can be explained by the
longstanding and predominant use of PI-based regimens in
Japan, including darunavir and atazanavir in both first-line and
second-line regimens
Genetic linkage analysis provided more insights into the
composition of the viral population by showing that L90M, M46I
and M46L in many patients existed on separate viral genomes.
The capacity to identify linked mutations could be important for
understanding the persistence [38] and clinical impact of
mutant variants. A major factor that influences the persistence
of drug-resistant mutants in vivo is their relative replicative
capacity within the viral population. In vitro competition
experiments conducted in the absence of drugs have shown
that drug resistance mutations impair replicative fitness by
different degrees. For instance, the M46I, the K70R, the 215
intermediate mutations have a lesser impact on fitness than
L90M, K65R, and M184V [38-40], and, thus, such mutations
are likely to persist longer in vivo. Moreover, accumulation of
compensatory mutations such as L63P and A71V in protease
have been demonstrated to increase or restore replicative
fitness of PI resistant variants, and that once compensation has
taken place reversion to wildtype is prohibited by a less fit
intermediate [41]. This may explain, for example, the high
prevalence of M46I we detected in this study as bulk and
minority species.
Phylogenetic analysis showed the sequences of minority
M46I/L and L90M-positive amplicons were closely related to
their source bulk sequences, supporting that the minority
sequences detected were unique to the respective patients and
were not the result of contamination. A few cases possessing
the M46I mutation by bulk sequencing demonstrated a strongly
supported identity which was not biased by including the
resistance mutations in the analysis. However, with regard to
minority M46I variants, we found they did not cluster closely
with viruses from persons with majority-level M46I. This
suggested that at least two pairs with majority-level M46I were
phylogenetically related whereas those with minority M46I were
scattered among the transmitted virus population, unrelated to
any of the other cases in our analysis. While the sequence
lengths used in the analysis might limit our ability to draw
robust bootstrap values deeper in the tree nodes, the
sequences for the pairs within the two clusters were identical
with the exception of a few positions with mixed bases, and
were further supported by high bootstraps.
The ability to conduct surveillance of minority-level drug
resistance mutations is an important advancement to help
understand transmission of HIV drug resistance in Japan. The
finding from our select analysis of mutations of interest cannot
be extrapolated to all codons associated with drug resistance;
however, these results suggest that a substantial proportion of
drug resistance-associated mutations are persist at low levels
by the time HIV-infected persons are diagnosed and
genotyped. Using an approach that can more broadly identify
variants, such as next-generation sequencing [42-45], may
identify other mutations that would further increase the
prevalence of drug resistance. However, because the more
commonly transmitted mutations are often targeted by AS-
PCR, any additional increase in mutation prevalence identified
by the more complex methods may be nominal. Hence, the
lower cost and simplicity of AS-PCR offer advantages for
routine surveillance, particularly when the sample burden may
be high.
In conclusion, the relationship between minority drug
resistance mutations and cART failure requires further
exploration; nevertheless, the findings point to difficulties in
getting infected persons diagnosed early and counseled to
prevent forward spread of drug resistance.
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